Harvard Business Review
SEPTEMBER 12, 2012
The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. See The Risks of Prescription Drugs (Columbia 2010).
Harvard Business Review
NOVEMBER 11, 2013
Develop standards for QIPs. Develop standards for meaningful participation by individual physicians. These standards were developed in partnership with the Mayo Clinic Quality Academy, which oversees teaching, training, coaching, and supporting Mayo’s 60,000 staff to improve patient outcomes, safety, and service.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Harvard Business Review
DECEMBER 6, 2012
For example, the SEC in 2010 had charged Goldman with misleading some of the parties to a billion dollar transaction (involving a complex derivative called a synthetic collateralized debt obligation), alleging specific facts about undisclosed conflicts of interest. Goldman settled within months for $550 million.
Harvard Business Review
FEBRUARY 3, 2017
By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. For instance, 60 institutional investors, collectively managing more than $5.5
Harvard Business Review
MARCH 2, 2017
On February 3 President Trump issued an executive order directing the Treasury Department to conduct a sweeping review of financial regulation, including Dodd-Frank , the financial reform bill passed, in 2010, as part of the Obama administration’s response to the 2008 financial crisis and subsequent recession.
Expert insights. Personalized for you.
15 
Let's personalize your content